Any content you receive is for information purposes only. Always conduct your own research. *Sponsored
See Why Paul Prescott Has (Nasdaq: MODD) On The Watchlist
This Morning—Wednesday, June 24, 2026
Don’t Miss Our Next Update—Get Real-Time Alerts Sent Directly To Your Phone. Up To 10X Faster Than Email. Check Out MODD While It’s Still Early… June 24, 2026 Dear Reader, Many companies spend years pursuing FDA clearance. Modular Medical, Inc. (Nasdaq: MODD) achieved it. Now comes the next phase. On April 9, 2026, the company received FDA 510(k) clearance for its Pivot™ insulin patch pump, opening the door to commercial sales in the United States. Less than two months later, MODD launched PivotPump.com and reiterated its timeline for initial patient shipments before the end of Q2 2026. That addressable segment, according to MODD, represents a potential $3B market. But what caught our attention wasn't simply the regulatory milestone. It was the population the company is targeting. According to MODD, roughly 4.8M Americans require daily insulin, while only a minority currently use pump-based therapy. The company believes many adults remain on injections because existing systems can be expensive, complex, or difficult to integrate into everyday life. That's the gap Pivot was designed to address. Combined with a founder who previously created Tandem Diabetes Care and designed the T insulin pump, MODD is entering commercialization with both a newly cleared product and a leadership team familiar with the diabetes technology landscape. These are only some of the reasons why MODD is topping our watchlist this morning—Wednesday, June 24, 2026. 
Keep in mind, MODD has less than 2.5M shares listed as available to the public. When companies have public floats this small, the potential exists for big moves if demand begins to shift. The founder behind MODD has a background closely tied to one of the most recognized names in diabetes technology. Paul DiPerna previously founded Tandem Diabetes Care in 2005 and invented and designed its T:Slim insulin pump—one of the most recognized names in the diabetes technology space. He applied that same engineering discipline to MODD, this time with a focus on eliminating the tradeoffs that have kept a large portion of insulin-dependent patients on injections rather than pump therapy. Beyond the U.S., MODD is targeting CE Mark approval for European markets, with a timeline of Q4 2026 or Q1 2027. That international pathway represents a second wave of addressable patients behind the U.S. commercial launch—and it's already in motion. Here's what you need to know about MODD. About Modular Medical, Inc. (Nasdaq: MODD)
Modular Medical, Inc. is a San Diego-based development-stage medical device company focused on the design, development, and commercialization of next-generation insulin delivery technology. Its mission, stated plainly, is to provide "diabetes care for the rest of us"—expanding access to the highest standard of glycemic control beyond what the company calls "superusers" of traditional pump systems. The company's flagship product is the Pivot™ insulin delivery system—the first two-part tubeless patch pump designed for adults with type 1 or type 2 diabetes. The Pivot combines a reusable controller with a disposable cartridge module, giving patients a tubeless design, 3 mL removable reservoir, disposable battery, smartphone-based dosing and monitoring, and an on-device bolus button for dosing without a phone. In plain English, it was built to reduce the cost, complexity, and wearability issues that have kept many insulin-dependent adults on daily injections instead of pump therapy. Modular Medical's scalable, low-cost manufacturing platform is designed to address this gap at accessible price points, while a software roadmap including variable bolus, improved alarms, and ACE/AID compatibility is already in development. The company filed for FDA 510(k) clearance for the Pivot in November 2025 and received clearance on April 9, 2026. It is also pursuing CE Mark approval for European markets, targeting Q4 2026 or Q1 2027, and has retained BSI Group as its notified body for that process. Diabetes Technology and Insulin Delivery
The diabetes technology sector sits at the intersection of two converging forces: a growing global disease burden and a persistent under-penetration of pump-based insulin therapy. Together, they define the structural opportunity that MODD is positioning to capture. Consider the base figures. There are approximately 4.8M Americans who require daily insulin. Of those, the company notes that only roughly 20% currently use an insulin pump—meaning some 3.8M insulin-dependent adults in the U.S. alone remain on multiple daily injections (MDI). The global insulin pump market is sized at approximately $8B, according to data cited in Modular Medical's own filings. The subsegment specifically targeted by Pivot—adult "almost-pumpers"—represents what the company has characterized as a $3B addressable market. 
The reason for that gap between disease burden and device adoption is well-documented: traditional insulin pumps are expensive, technically demanding, and often designed for younger, tech-comfortable patients. The market structure has historically favored established players like Medtronic, Insulet (Omnipod), and Tandem Diabetes Care—none of which have specifically engineered their flagship products around simplicity and price accessibility for the broader adult MDI population. MODD's Pivot is architecturally different. It is designed from the ground up around the specific barriers that keep most insulin-dependent adults on injections: cost, tube complexity, wearability, and the learning curve. The two-part removable design—reusable controller, disposable cartridge—creates a recurring revenue model while keeping per-unit costs accessible. The smartphone-first bolus architecture removes the need for a dedicated handheld controller, reducing both device cost and patient complexity. The broader diabetes device sector is expanding rapidly. The global insulin pump market, while already large, is benefiting from increasing type 2 diabetes adoption—a historically underpenetrated but rapidly growing segment for device-based therapy. Automated insulin delivery (AID) features, which MODD has on its software roadmap, represent the next major frontier in clinical differentiation. If Pivot reaches AID compatibility, its addressable market expands further still. Recent Milestones
PivotPump.com Launch
MODD launched PivotPump.com, a patient-focused digital presence designed to support individuals exploring insulin pump therapy. The site launch accompanied confirmation that the company remains on track for commercial launch in fall 2026, with initial patients expected in June 2026. FDA 510(k) Clearance for Pivot™ The defining milestone of 2026: MODD received FDA 510(k) clearance for the Pivot™ tubeless insulin patch pump, clearing the path for U.S. commercial sales. The Pivot is the first two-part tubeless patch pump with a removable 3 mL reservoir, disposable battery, smartphone connectivity, and initial production capacity supporting approximately 6,000 users. 7 Reasons Why MODD is At The Top Of My Screen This Morning—Wednesday, June 24, 2026…
1. Small Float: With fewer than 2.5M shares listed as available to the public, MODD’s small float could have the potential to witness big moves if demand begins to shift. 2. Large Market: MODD is focused on a patient population that the company estimates represents a $3B segment within the broader insulin delivery market. 3. FDA Cleared: MODD received FDA 510(k) clearance for its Pivot™ insulin patch pump on April 9, 2026, clearing the path for commercial sales in the United States. 4. Launch Ahead: MODD expects initial patient shipments by the end of Q2 2026 and is targeting a full commercial launch in fall 2026. 5. Adoption Gap: MODD was built to address the fact that approximately 4.8M Americans require daily insulin, while only about 20% currently use an insulin pump. 6. Founder Experience: MODD was founded by Paul DiPerna, who also founded Tandem Diabetes Care and designed the widely recognized T insulin pump. 7. Global Expansion: MODD is pursuing CE Mark approval for European markets, with a target timeline of Q4 2026 or Q1 2027 following its planned U.S. commercial rollout. Check Out MODD While It’s Still Early… 
When you step back and look at the full picture, it's easy to see why MODD has captured our attention as today’s session unfolds. The company has already achieved a major regulatory milestone with FDA 510(k) clearance, is approaching initial patient shipments, and is targeting a broader commercial rollout later this year. At the same time, it is pursuing expansion into European markets while addressing a segment that the company estimates represents a $3B market. Add in a founder with deep experience in diabetes technology, a product specifically designed for adults who have remained on daily injections, and a public float of fewer than 2.5M shares, and you have a company entering what could be a pivotal period in its development. Whether you're following regulatory milestones, commercial launch timelines, emerging medical-device stories, or companies targeting large underserved patient populations, MODD is one to keep an eye on. We have all eyes on MODD this morning. Take a look at MODD while it’s still early. Sincerely, Paul Prescott
Co-Founder & Managing Editor
Street Ideas Newsletter |
No comments:
Post a Comment